Ascentage Pharma Group International (AAPG)vsargenx NV ADR (ARGX)
AAPG
Ascentage Pharma Group International
$22.32
0.00%
HEALTHCARE · Cap: $1.79B
ARGX
argenx NV ADR
$677.50
-0.64%
HEALTHCARE · Cap: $41.09B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 985% more annual revenue ($4.24B vs $390.60M). ARGX leads profitability with a 30.5% profit margin vs -296.8%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
AAPG
Avoid15
out of 100
Grade: F
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$677.50
$544.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 79.7x book value
ROE of -159.7% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
AAPG has a balanced fundamental profile.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : AAPG
The primary concerns for AAPG are EPS Growth, Market Cap, Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
AAPG profiles as a turnaround stock while ARGX is a growth play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.87 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (63/100 vs 15/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?